2017
Risk of Acute Liver Injury With Antiretroviral Therapy by Viral Hepatitis Status
Gowda C, Newcomb CW, Liu Q, Carbonari DM, Lewis JD, Forde KA, Goldberg DS, Reddy KR, Roy JA, Marks AR, Schneider JL, Kostman JR, Tate JP, Lim JK, Justice AC, Goetz MB, Corley DA, Re V. Risk of Acute Liver Injury With Antiretroviral Therapy by Viral Hepatitis Status. Open Forum Infectious Diseases 2017, 4: ofx012. PMID: 28470014, PMCID: PMC5407218, DOI: 10.1093/ofid/ofx012.Peer-Reviewed Original ResearchSevere acute liver injuryAcute liver injuryViral hepatitis statusAntiretroviral therapyHepatitis statusAminotransferase elevationHazard ratioLiver aminotransferasesLiver injuryHigh riskHIV/viral hepatitisKaiser Permanente Northern CaliforniaVeterans Aging Cohort StudyNonnucleoside reverse transcriptase inhibitorAbacavir/lamivudineProtease inhibitor useTenofovir/emtricitabineAging Cohort StudyHuman immunodeficiency virusRisk of hepatotoxicityConfidence intervalsReverse transcriptase inhibitorART initiationCoinfected PatientsART regimens
2016
Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras
Klein MB, Althoff KN, Jing Y, Lau B, Kitahata M, Re V, Kirk GD, Hull M, Kim HN, Sebastiani G, Moodie EE, Silverberg MJ, Sterling TR, Thorne JE, Cescon A, Napravnik S, Eron J, Gill MJ, Justice A, Peters MG, Goedert JJ, Mayor A, Thio CL, Cachay ER, Moore R, Research and Design of IeDEA F, Kirk G, Benson C, Bosch R, Boswell S, Mayer K, Grasso C, Hogg R, Harrigan P, Montaner J, Cescon A, Samji H, Brooks J, Buchacz K, Gebo K, Moore R, Moore R, Rodriguez B, Horberg M, Silverberg M, Thorne J, Goedert J, Jacobsonc L, D'Souza G, Klein M, Rourke S, Burchell A, Rachlis A, Hunter-Mellado R, Mayor A, Gill M, Deeks S, Martin J, Patel P, Brooks J, Saag M, Mugavero M, Willig J, Eron J, Napravnik S, Kitahata M, Crane H, Kim H, Drozd D, Sterling T, Haas D, Bebawy S, Turner M, Justice A, Dubrow R, Fiellin D, Gange S, Anastos K, Moore R, Saag M, Gange S, Kitahata M, Althoff K, McKaig R, Justice A, Freeman A, Moore R, Freeman A, Lent C, Kitahata M, Van Rompaey S, Crane H, Drozd D, Morton L, McReynolds J, Lober W, Gange S, Althoff K, Abraham A, Lau B, Zhang J, Jing J, Golub E, Modur S, Wong C, Hogan B, Tong W, Liu B. Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras. Clinical Infectious Diseases 2016, 63: 1160-1167. PMID: 27506682, PMCID: PMC5064164, DOI: 10.1093/cid/ciw531.Peer-Reviewed Original ResearchConceptsEnd-stage liver diseaseUse of antiretroviralsESLD riskAntiretroviral therapyLiver diseaseNorth American AIDS Cohort CollaborationTime-updated CD4 cell countModern antiretroviral therapy (ART) eraAntiretroviral therapy eraTenofovir-based regimensCD4 cell countModern antiretroviral therapyHuman immunodeficiency virusIncidence rate ratiosRate ratioCohort CollaborationCoinfected PersonsTherapy eraHCV therapyHIV RNAHepatitis BHepatitis statusImmunodeficiency virusC virusAntiretroviral era